LYSOGENE Logo

LYSOGENE

LYS | PA

Overview

Corporate Details

ISIN(s):
FR0013233475
LEI:
969500T64RILK1RD0852
Country:
France
Address:
18 RUE JACQUES DULUD, 92200 NEUILLY-SUR-SEINE
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Lysogene’s determination to succeed is rooted in our deep understanding of the impact central nervous system (CNS) diseases have on patients and families, and springs from our founder whose own child was affected by a neurodegenerative disease. Our mission is to discover and develop innovative therapies to transform the lives of people with rare central nervous system disorders. Lysogene is a biopharmaceutical gene therapy company with lead programs in neurodegenerative lysosomal storage disorders that affect children.

Social Media

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for LYSOGENE and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2023-05-26 17:32
Delisting Announcement
Informations privilégiées / Autres communiqués
French 84.9 KB
2023-05-26 17:32
Delisting Announcement
Inside Information / Other news releases
English 83.2 KB
2023-05-26 10:00
Delisting Announcement
Informations privilégiées / Autres communiqués
French 85.6 KB
2023-05-26 10:00
Legal Proceedings Report
Inside Information / Other news releases
English 83.5 KB
2023-05-15 18:00
Legal Proceedings Report
Inside Information / Other news releases
English 83.5 KB
2023-05-15 18:00
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 85.6 KB
2023-04-29 18:00
Report Publication Announcement
Inside Information / News release on accounts, results
English 82.9 KB
2023-04-29 18:00
Delisting Announcement
Informations privilégiées / Communiqué sur comptes, résultats
French 85.1 KB
2023-04-14 18:00
M&A Activity
Inside Information / Other news releases
English 83.2 KB
2023-04-14 18:00
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 85.4 KB
2023-03-24 20:00
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 95.8 KB
2023-03-24 20:00
Regulatory News Service
Inside Information / Other news releases
English 93.5 KB
2023-02-16 18:00
Delisting Announcement
Inside Information / Other news releases
English 107.8 KB
2023-02-16 18:00
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 110.2 KB
2023-02-03 18:00
Board/Management Information
Informations privilégiées / Autres communiqués
French 91.3 KB

Automate Your Workflow. Get a real-time feed of all LYSOGENE filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for LYSOGENE via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
DBV Technologies Logo
Developing a non-invasive skin patch for epicutaneous immunotherapy to treat food allergies.
France DBV
DEINOVE Logo France ALDEI
Delta Drone Logo
Develops proprietary drone tech for logistics, security & military and consolidates the industry.
France ALDR
Deutsche Biotech Innovativ AG Logo
Develops biomarker-guided monoclonal antibodies for serious diseases like septic shock.
Germany DBI
DexTech Medical AB Logo
Developing pharmaceuticals for urological oncology using its proprietary GuaDex technology platform.
Sweden DEX
DG INNOVATE PLC Logo
Develops sustainable tech for EV drivetrains and next-gen energy storage materials.
United Kingdom DGI
Dicot Pharma AB Logo
Developing next-gen potency drugs for erectile dysfunction and premature ejaculation.
Sweden DICOTBT
Israel DNA
Ectin Research AB Logo
Clinical-stage pharma developing novel cancer therapies, focusing on metastatic bladder cancer.
Sweden ECTIN B
Elanix Biotechnologies AG Logo Germany ELN

Talk to a Data Expert

Have a question? We'll get back to you promptly.